Abstract
Clinical trials often represent an increasingly important option for patients with cancer, thus oncologists participating in clinical research need to consider and address the financial burden associated with trial participation. Future research efforts should focus on developing formal screening tools to identify and monitor for financial burden among clinical trial participants.